Sector News

Which pharma execs win the popularity contest?

May 24, 2017
Life sciences

Sometimes adult life sends us through a disturbing time warp. It’s much too reminiscent of high school.

The cool kids’ cafeteria table (or parking lot, where I grew up) becomes the cool grown-up party at J.P. Morgan, for instance. Step into biopharma Twitter, where the snark level sometimes hits Mean Girls levels.

But today, it’s the “best all-around” votes senior year echoed in post-high school reality. Only instead of the most popular graduating senior, these votes chose the most congenial CEOs in biopharma.

The business-information analysts over at Owler sifted through various data streams, including its own CEO rating tool (smile, frown or in-between) to come up with a ranking of the best-liked pharma leaders. The top 10 is mostly packed with Big Pharma’s top dogs, with a couple of surprises in the mix.

Including No. 1, Sanjay Bhatia of Laborate Pharmaceuticals, a small, privately held drugmaker in Delhi, India. His approval rating with Owler’s tool? A stunning 99 out of 100. And it’s not because he has 100 employees who all voted with a smile. Laborate has an estimated 5,180 staffers and 1,980 followers on the Owler site.

Roche and its Genentech unit swept second and third, with Roche’s Severin Schwan in second place with a 92.9 approval rating. Bill Anderson at Genentech clocked an 87.7. Switzerland-based Roche bought the share of California-based Genentech it didn’t already own back in 2009, and the Genentech side of the business has delivered some of Roche’s biggest-selling drugs in the last few years.

AbbVie’s Richard Gonzalez comes in fourth with an 83.8 approval rating—he’s been at the helm at that company since it was spun off by Abbott Laboratories in 2013. He’s consistently among the highest-paid CEOs in the industry, and while popularity among staff isn’t among his compensation metrics, driving “employee engagement” is.

Rounding out the top five is Shire’s Flemming Ornskov, whose most recent claim to fame is the company’s buyout of Bioverativ, the hemophilia unit spun off by Baxter last year.

The rest of the top 10? Merck’s Ken Frazier; GlaxoSmithKline’s Emma Walmsley, who’s brand-new to the Glaxo CEO post; Johnson & Johnson’s Alex Gorsky; and Bayer’s relatively new chief, Werner Baumann. Steven H. Collis, CEO of the drug distributor AmerisourceBergen, came in seventh. All of their ratings fell in the 70s.

This is not, of course, a randomized, statistically weighted survey with a p-value of less than 0.05. For all we know, one or more of the CEOs in the top 10 has a master plan to boost online ratings—good reviews, up votes, etcetera. But a couple of facts to walk away with are these: As a group, biotech and pharma CEOs came in 13th, ratings-wise, when measured against other industries.

Pretty average for likability, an Owler spokeswoman said in a statement. Those ratings “suggest that CEOs leading at pharma and biotech companies, in terms of favorability, are in the middle of the pack relative to CEOs in other industries.”

By Tracy Staton

Source: Fierce Pharma

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]